Close

Five Prime Therapeutics (FPRX) Says Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at SITC

October 11, 2017 4:23 PM EDT Send to a Friend
Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login